Maia Biotechnology Clinical Trial Data
MAIA Biotechnology reported updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating ateganosine (THIO) in patients with advanced non-small cell lung cancer (NSCLC). The trial demonstrated an 88% disease control rate (DCR) in third-line patients who had progressed after prior immunotherapy and chemotherapy, significantly higher than the 25-35% DCR typically seen with standard chemotherapy.